These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 397063)

  • 1. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.
    Ziegler EJ; McCutchan JA; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia.
    McCutchan JA; Ziegler EJ; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():77-80. PubMed ID: 397064
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiserum treatment of gram-negative bacteremia.
    Braude AI; Ziegler EJ; McCutchan JA
    Schweiz Med Wochenschr; 1978 Dec; 108(48):1872-6. PubMed ID: 362528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
    Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
    N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core.
    Ziegler EJ; McCutchan JA; Douglas H; Braude AI
    Trans Assoc Am Physicians; 1981; 94():39-43. PubMed ID: 7046193
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anti-endotoxin core glycolipid antibody: the preparation of immune serum of E. Coli J5].
    Xu XN; Li ZJ; Li YP
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Jun; 16(6):358-60. PubMed ID: 15182450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.
    Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM
    J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of Re-LPS antiserum on experimental multiple system organ failure.
    Yao YM; Tian HM; Wang YP; Sheng ZY; Shi ZG; Xu SH
    Chin Med J (Engl); 1992 Oct; 105(10):833-8. PubMed ID: 1291201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.
    Cross AS; Opal SM; Warren HS; Palardy JE; Glaser K; Parejo NA; Bhattacharjee AK
    J Infect Dis; 2001 Apr; 183(7):1079-86. PubMed ID: 11237833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.
    Braude AI; Ziegler EJ; Douglas H; McCutchan JA
    J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.
    Ziegler EJ; Douglas H; Braude AI
    J Clin Invest; 1973 Dec; 52(12):3236-8. PubMed ID: 4584346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological intervention in endotoxin shock.
    Ziegler EJ
    Prog Clin Biol Res; 1988; 272():319-25. PubMed ID: 3293079
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.
    Appelmelk BJ; Verwey-van Vught AM; Maaskant JJ; Schouten WF; Thijs LG; Maclaren DM
    Antonie Van Leeuwenhoek; 1986; 52(6):537-42. PubMed ID: 3545072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protective effect of antiserum to Re-LPS on experimental multiple organ failure].
    Yao YM
    Zhonghua Wai Ke Za Zhi; 1992 Apr; 30(4):244-7, 256. PubMed ID: 1473411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
    Young LS; Stevens P; Ingram J
    J Clin Invest; 1975 Oct; 56(4):850-61. PubMed ID: 1099119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.